Market revenue in 2021 | USD 417.5 million |
Market revenue in 2030 | USD 2,840.1 million |
Growth rate | 23.7% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.57% in 2021. Horizon Databook has segmented the U.S. non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
A chronic, progressive condition known as NASH causes fatty liver and liver cell damage before progressing to cirrhosis, fibrosis, and Hepatocellular Cancer (HCC). The diagnosis requires a liver biopsy, however, owing to the expense and invasiveness of the procedure, NASH is still underdiagnosed.
To assess liver health, several companies have developed blood- and imaging-based biomarkers, however, neither of these technologies has been systematically evaluated nor validated against the existing gold standard of liver biopsy.
NIMBLE assessed the existing NASH biomarkers to determine those with enough encouraging data to support further validation. These potential biomarkers will be thoroughly investigated by NIMBLE to gauge their effectiveness in comparison with the gold standard and determine whether they are suitable for widespread use in clinical trials, possibly in place of liver biopsy.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into U.S. non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account